Concentrated extracts of an edible brown seaweed. The most consistently measured effect is a smaller blood-sugar rise after a starchy meal, with smaller, less certain reductions in cholesterol, body fat, blood pressure and night-time wakefulness. Most trials were run by sellers and judged low quality. Seaweed-derived products can carry enough iodine to unsettle the thyroid, and can concentrate arsenic. (Full Review)

Protocol

Standard supplement protocol

72–144 mg/day

Phlorotannin-standardised extract for at least 12 weeks

Glycemic protocol

600–1,500 mg/day

Dieckol-enriched extract immediately before the largest carbohydrate meal; exceeds the regulatory intake ceiling

Sleep protocol

500 mg

Standardised phlorotannin 30–60 minutes before bed

Time to effect

Post-meal glucose

Immediate

Blunting occurs within a single meal

Lipids, body fat, blood pressure

12 weeks

Changes took the full 12 weeks to become measurable, so shorter self-experiments show nothing

Sleep maintenance

1 week

Reduced wakefulness after falling asleep was measured in a one-week trial

Benefits

Medium: Lower post-meal blood glucose; reductions in total and LDL cholesterol

Low: Better sleep maintenance; reduced body fat and waist circumference; lower systolic blood pressure; relief of cough and sputum; endurance performance

Speculative: Topical and injected hair growth support; neuroprotection and slower cognitive aging; lower systemic inflammation; reduced allergic responses; anti-cancer activity; protection against skin photoaging and pigmentation

Contraindications

Pregnancy and lactation

Children under 12 years

Graves' disease, toxic nodular goitre, or Hashimoto thyroiditis with thyroid peroxidase antibodies above 60 IU/mL

Prior iodine-induced thyroid dysfunction, or urinary iodine above 300 µg/L

Known seaweed, algal or iodine hypersensitivity

Platelet count below 100 × 10⁹/L, or within 7 days of any surgery or dental extraction

Child-Pugh Class B or C liver impairment, or eGFR below 30 mL/min/1.73 m²

Key Interactions

Insulin and sulfonylureas (glimepiride, glipizide, gliclazide)

α-Glucosidase inhibitors (acarbose, miglitol) and gut-hormone-based drugs (sitagliptin, semaglutide)

Levothyroxine and antithyroid drugs (methimazole, propylthiouracil)

Sedatives and hypnotics (lorazepam, zolpidem, gabapentin, pregabalin)

Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, low-dose aspirin)

Over-the-counter medications (NSAIDs: ibuprofen, naproxen, aspirin; sedating antihistamines: diphenhydramine, doxylamine; iodine-containing expectorants, potassium iodide)

Supplement interactions (non-heme iron and zinc binding)

Additive supplements affecting glucose (berberine, chromium picolinate, white kidney bean extract, cinnamon extract)

Additive supplements affecting sedation, bleeding and iodine (melatonin, valerian, L-Theanine, fish oil, nattokinase, high-dose vitamin E, kelp, bladderwrack)

Other interventions (prolonged fasting, ketogenic diets, post-bariatric-surgery anatomy)

Risk & Side Effects

High: Iodine overload and thyroid dysfunction from whole-alga forms

Medium: Arsenic and heavy-metal exposure from algal material; sedation and additive central nervous system depression

Low: Gastrointestinal intolerance; blood sugar falling too low with glucose-lowering therapy; bleeding-time prolongation

Speculative: Interference with drug metabolism; uncertainty at doses above the regulatory ceiling

Monitoring

Marker	Target	Why
Post-meal glucose (90 min)	100–120 mg/dL	The effect with the strongest human support
Fasting glucose	75–86 mg/dL	Detects drift in overall glycemic control
HbA1c	4.9–5.3%	Integrates three months of glucose exposure
Fasting insulin	<5 µIU/mL	Tracks insulin resistance, which trials measured only indirectly
LDL cholesterol	<100 mg/dL	The lipid endpoint the pooled analysis moved
Apolipoprotein B	<80 mg/dL	Counts artery-damaging particles more reliably than LDL cholesterol
High-sensitivity C-reactive protein	<0.5 mg/L	Tests the anti-inflammatory claim directly
TSH	0.5–2.0 mIU/L	Earliest signal of iodine-driven thyroid disturbance
Free T4 and free T3	Free T4 1.0–1.5 ng/dL; free T3 3.0–4.0 pg/mL	Confirms whether a TSH shift is real
Thyroid peroxidase antibodies	<9 IU/mL	Identifies autoimmune thyroid disease, the main iodine contraindication
Urinary iodine	100–199 µg/L	Quantifies the actual iodine load from any seaweed-derived product
Urinary inorganic arsenic (species-resolved)	<15 µg/L	Separates real arsenic exposure from harmless seafood forms
ALT	10–26 U/L (men), 10–19 U/L (women)	Screens for any liver signal from a novel botanical
Platelet count and INR	Platelets 150–400 × 10⁹/L; INR at the prescriber's target	Bounds the theoretical bleeding risk
Ferritin	50–150 ng/mL	Polyphenols reduce non-heme iron absorption

Cadence: Baseline, then two weeks of post-meal readings; thyroid and metabolic markers at 8–12 weeks, then every 6–12 months; urinary iodine at 12 weeks then annually; coagulation within two weeks on anticoagulants.

Qualitative Assessment

Sleep continuity — number and length of night-time awakenings
Morning sedation or slowed reaction time
Post-meal energy and sleepiness
Bloating, flatulence and stool consistency in the first two weeks
Cough and sputum burden, if used for respiratory symptoms
Waist circumference, measured monthly

Ecklonia cava for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment